0001104659-24-026040.txt : 20240221 0001104659-24-026040.hdr.sgml : 20240221 20240221161656 ACCESSION NUMBER: 0001104659-24-026040 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ben-Kiki Tomer CENTRAL INDEX KEY: 0002011990 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37704 FILM NUMBER: 24659716 MAIL ADDRESS: STREET 1: C/O DARIOHEALTH CORP. STREET 2: 322 W 57TH ST. #33B CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DarioHealth Corp. CENTRAL INDEX KEY: 0001533998 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 452973162 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 322 W 57TH ST. #33B CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 972-4-770-6377 MAIL ADDRESS: STREET 1: 322 W 57TH ST. #33B CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: LabStyle Innovations Corp. DATE OF NAME CHANGE: 20111101 4 1 tm246888-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-02-15 0 0001533998 DarioHealth Corp. DRIO 0002011990 Ben-Kiki Tomer 122 W 57TH ST, #33B NEW YORK NY 10019 0 1 0 0 Chief Operating Officer 0 Stock Option (right to buy) 2.55 2024-02-15 4 A 0 717947 0 A 2034-02-15 Common Stock 717947 717947 D Stock Option (right to buy) 2.55 2024-02-15 4 A 0 300000 0 A 2034-02-15 Common Stock 300000 300000 D The options vest as follows: 291,742 shares vest immediately, and the remaining 426,205 shares vest over two years in eight equal quarterly amounts, subject to subject to the Reporting Person's continued services to the Issuer on the applicable vesting date. The options vest immediately upon achieving certain milestones relating to the achievement of revenues (on a U.S. generally accepted account principals basis) for the year ending December 31, 2024, the achievement of certain operating expense targets for the years ending December 31, 2024 and December 31, 2025, the ability to generate software value from funds invested and meet product roadmap and the retention of key employees post transaction, subject in each case to the Reporting Person's continued services to the Issuer on the applicable vesting date. /s/ Tomer Ben-Kiki 2024-02-21